Allogene Therapeutics Inc (NASDAQ: ALLO) is -15.26% lower on its value in year-to-date trading and has touched a low of $2.01 and a high of $5.78 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ALLO stock was last observed hovering at around $2.62 in the last trading session, with the day’s gains setting it 0.1%.
Currently trading at $2.72, the stock is 0.93% and 1.01% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.93 million and changing 3.82% at the moment leaves the stock -15.66% off its SMA200. ALLO registered -19.05% loss for a year compared to 6-month loss of -39.01%. The firm has a 50-day simple moving average (SMA 50) of $2.6788 and a 200-day simple moving average (SMA200) of $3.22645.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 1.49% gain in the last 1 month and extending the period to 3 months gives it a 11.48%, and is -6.53% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.32% over the week and 7.95% over the month.
Allogene Therapeutics Inc (ALLO) has around 233 employees, a market worth around $568.78M and $0.09M in sales. Profit margin for the company is -323780.23%. Distance from 52-week low is 35.32% and -52.90% from its 52-week high. The company has generated returns on investments over the last 12 months (-46.25%).
The EPS is expected to grow by 32.39% this year
243.0 institutions hold shares in Allogene Therapeutics Inc (ALLO), with institutional investors hold 97.78% of the company’s shares. The shares outstanding are 167.13M, and float is at 136.57M with Short Float at 28.69%. Institutions hold 80.69% of the Float.
The top institutional shareholder in the company is FMR LLC with over 31.26 million shares valued at $72.83 million. The investor’s holdings represent 18.4816 of the ALLO Shares outstanding. As of 2024-06-30, the second largest holder is TPG GP A, LLC with 18.72 million shares valued at $43.61 million to account for 11.0663 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 16.45 million shares representing 9.7238 and valued at over $38.32 million, while VANGUARD GROUP INC holds 4.8458 of the shares totaling 8.2 million with a market value of $19.1 million.
Allogene Therapeutics Inc (ALLO) Insider Activity
Allogene Therapeutics Inc disclosed in a document filed with the SEC on Jun 18 ’24 that MESSEMER DEBORAH M. (Director) sold a total of 18,641 shares of the company’s common stock. The trade occurred on Jun 18 ’24 and was made at $2.28 per share for $42488.0. Following the transaction, the insider now directly holds 0.17 million shares of the ALLO stock.
Still, SEC filings show that on May 30 ’24, Humer Franz B (Director) disposed off 11,200 shares at an average price of $2.34 for $26181.0. The insider now directly holds 255,253 shares of Allogene Therapeutics Inc (ALLO).
